Formycon AG (ETR:FYB)
Germany flag Germany · Delayed Price · Currency is EUR
23.35
-0.35 (-1.48%)
Jun 2, 2025, 2:30 PM CET

Formycon AG Company Description

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland.

It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names.

The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names.

It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, hodgkin’s lymphoma, urothelial carcinomas, tumors in the head and neck area, other tumor diseases; and FYB208 and FYB209 that is indicated for immunology areas.

The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Formycon AG
Formycon AG logo
Country Germany
Founded 1999
Industry Biotechnology
Sector Healthcare
Employees 250
CEO Stefan Glombitza

Contact Details

Address:
Fraunhoferstrasse 15
Planegg, 82152
Germany
Phone 49 89 864 667 100
Website formycon.com

Stock Details

Ticker Symbol FYB
Exchange Deutsche Börse Xetra
Fiscal Year January - December
Reporting Currency EUR
ISIN Number DE000A1EWVY8
SIC Code 2836

Key Executives

Name Position
Dr. Stefan Glombitza Chief Executive Officer, Chief Operating Officer and Chair of the Executive Board
Dr. Nicolas Combe Ph.D. Co-Founder
Enno Spillner Chief Financial Officer and Member of the Executive Board
Dr. Andreas Seidl Chief Scientific Officer and Member of the Executive Board
Nicola Mikulcik Chief Business Officer and Member of the Executive Board
Dr. Friedrich-Wilhelm Steinweg Co-Founder
Sabrina Muller Director of Investor Relations and Corporate Communications